Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02205762 · ClinicalTrials.gov registry record · Phase 2

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by North American Consortium for Histiocytosis.

Recruiting
Registry status
Phase 2
Development phase
1,400
Enrollment target
20
Study locations

NCT02205762 is a Phase 2 study of Langerhans Cell Histiocytosis that is actively recruiting participants, run by North American Consortium for Histiocytosis. The registered enrollment target is 1,400 participants, above the 964-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02205762, a Phase 2 study of Langerhans Cell Histiocytosis, is actively recruiting participants, sponsored by North American Consortium for Histiocytosis.

RECRUITING
Registry status
Phase 2
Development phase
1,400 participants
Enrollment target
20
Study locations

Study Summary

The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).

Conditions Studied

Langerhans Cell Histiocytosis

Interventions

  • DRUG Prednisone
  • DRUG Methotrexate
  • DRUG Vinblastine
  • DRUG mercaptopurine
  • DRUG INDOMETHACIN

Study Locations (20)

California

  • Children's Hospital of Los Angeles - Los Angeles
  • Valley Children's Healthcare - Madera
  • UCSF Benioff Children's Hospital of Oakland - Oakland
  • Children's Hospital of Orange County - Orange
  • UCSF Helen Diller Family Cancer Center - San Francisco

Kentucky

  • University of Kentucky A.B.Chandler Medical Center - Lexington
  • University of Louisville, Norton Children's Hospital - Louisville

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Alabama

  • Children's of Alabama - Birmingham

Arizona

  • Phoenix Children's Hospital - Phoenix

Arkansas

  • Arkansas Children's Hospital - Little Rock

Connecticut

  • Connecticut Children's Medical Center - Hartford

District of Columbia

  • Children's National Medical Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,400 participants
Start Date 2016-11-02
Est. Completion 2026-07
Phase Phase 2

Sponsor

North American Consortium for Histiocytosis

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02205762

The ClinicalTrials.gov registry entry for NCT02205762 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 964-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (45% higher). The listed sponsor is North American Consortium for Histiocytosis, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 5 interventions - of which Prednisone is the first listed.

NCT02205762 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Kentucky, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02205762 about?

NCT02205762 is a clinical study titled "LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis". The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).

What is the current status of trial NCT02205762?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,400 participants. The study started on 2016-11-02. Estimated completion is 2026-07.

What conditions does trial NCT02205762 study?

This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.

What interventions are being tested in trial NCT02205762?

The interventions under investigation include: Prednisone (DRUG), Methotrexate (DRUG), Vinblastine (DRUG), mercaptopurine (DRUG), INDOMETHACIN (DRUG).

Who is sponsoring clinical trial NCT02205762?

This trial is sponsored by North American Consortium for Histiocytosis, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02205762 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Langerhans Cell Histiocytosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Langerhans Cell Histiocytosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.